Product
Supplier
Encyclopedia
Inquiry
Home > Active Pharmaceutical Ingredients > Other Chemical Drugs > Retatrutide for Sale > Retatrutide Retatrutide safe delivery strong Lyophilized powder Vial
Retatrutide Retatrutide  safe delivery strong Lyophilized powder Vial buy - large image1
Retatrutide Retatrutide  safe delivery strong Lyophilized powder Vial buy - image1
Retatrutide Retatrutide  safe delivery strong Lyophilized powder Vial buy - image2
Retatrutide Retatrutide  safe delivery strong Lyophilized powder Vial buy - image3
Retatrutide Retatrutide  safe delivery strong Lyophilized powder Vial buy - image4
Retatrutide Retatrutide  safe delivery strong Lyophilized powder Vial buy - image5
Retatrutide Retatrutide  safe delivery strong Lyophilized powder Vial buy - image6

Retatrutide Retatrutide safe delivery strong Lyophilized powder Vial

TDS 6934 Inquiries

Unit Price: Get Latest Price
CAS No.:

2381089-83-2

Grade:

Pharmaceutical Grade

Content:

99%

Port:

Guangzhou

Brand:

Guangsheng

Packaging:

5-60mg*10vials

Price valid (until):

2026-02-14

Company Type:
Trader
Location:
China
Qualification:
Main Products:

beaty prodt

  • Product Description

  • Seller Information

  • Inquiry History

  • Description


      Product Detail  


    Name:  Lynn
    Wechat:  15914422644

    Tel:+86  15914422644

    Whatsapp: + 852 6252 8290

    Email:   guangsheng 5   @zgguangsheng.com


      Product Detail  




    Shop Retatrutide Retatrutide  safe delivery strong Lyophilized powder Vial-Detailed Image 1

    1. Core Molecular & Physical Traits

    • Structure: 39-amino acid synthetic peptide with a lipid diacid moiety for extended half-life.
    • Formula/MW: C₂₂₃H₃₄₃F₃N₄₆O₇₀; 4845.44 Da.
    • Formulation: Subcutaneous injection (lyophilized powder), once-weekly dosing.
    • Pharmacokinetics: Half-life ~6 days; dose-proportional absorptionPubMed.
    • Purity: ≥99% (HPLC), ensuring high bioactivity.

    2. Mechanism of Action (Triple Receptor Synergy)

    Receptor Key Actions
    GLP-1R Glucose-dependent insulin secretion; glucagon suppression; delayed gastric emptying; enhanced satiety
    GIPR Improved insulin sensitivity; lipid metabolism regulation; synergizes with GLP-1R for weight loss
    GCGR Boosts energy expenditure; reduces hepatic fat deposition; enhances lipolysis

    Collectively, it curbs appetite, accelerates fat breakdown, improves glycemic control, and reduces liver fat.

    3. Clinical Efficacy Data

    Trial Duration Doses Key Outcomes
    Phase 2 (Obesity) 48 weeks 8/12 mg/week Avg. weight loss: 24–28.7% (vs. ~15% for dual agonists)
    Phase 3 (Triumph-4) 68 weeks 12 mg/week Max. weight loss 28.7%; reduced knee pain by 75.8%
    Type 2 Diabetes 24 weeks 4–12 mg/week HbA1c ↓1.8–2.2%; fasting glucose ↓30–40 mg/dL
    Hepatic Steatosis 24 weeks 8 mg/week Liver fat content ↓40–50%

    4. Safety & Tolerability

    • Common Side Effects: Mild–moderate, transient GI issues (nausea, diarrhea, vomiting).
    • Key Advantages: Low severe hypoglycemia risk (monotherapy); minimal impact on bone density/hormones.
    • Precautions: Avoid in medullary thyroid carcinoma, multiple endocrine neoplasia type 2, or hypersensitivity.

    5. Application Scenarios

    • Obesity: Long-term weight management (adjunct to lifestyle changes).
    • Type 2 Diabetes: Adjunct therapy for glycemic control and weight reduction.
    • Metabolic Comorbidities: Non-alcoholic fatty liver disease (NAFLD), knee osteoarthritis (weight-related).
    • Future Potential: NASH, cardiovascular risk reduction, and body composition improvement.

    6. Development Status

    As of early 2026, it is in late-stage Phase 3 trials (e.g., TRIUMPH program). Eli Lilly plans to file for FDA approval in 2026, with potential launch in 2027.
    Index Standard Test Method
    Appearance White to off-white lyophilized powder Visual Inspection
    Molecular Formula C₂₂₁H₃₄₂N₄₆O₆₈ Mass Spectrometry
    Molecular Weight 4731.33 Calculated & Verified by MS
    Solubility Soluble in water, dilute acid Shake Test (25℃)Sterility
    Sterility Meets pharmaceutical R&D standards Membrane Filtration Method



      About Us  


    Shop Retatrutide Retatrutide  safe delivery strong Lyophilized powder Vial-Detailed Image 2
    Shop Retatrutide Retatrutide  safe delivery strong Lyophilized powder Vial-Detailed Image 3
    Shop Retatrutide Retatrutide  safe delivery strong Lyophilized powder Vial-Detailed Image 4
    Shop Retatrutide Retatrutide  safe delivery strong Lyophilized powder Vial-Detailed Image 5
    Shop Retatrutide Retatrutide  safe delivery strong Lyophilized powder Vial-Detailed Image 6
    Shop Retatrutide Retatrutide  safe delivery strong Lyophilized powder Vial-Detailed Image 7
    Shop Retatrutide Retatrutide  safe delivery strong Lyophilized powder Vial-Detailed Image 8
    Shop Retatrutide Retatrutide  safe delivery strong Lyophilized powder Vial-Detailed Image 8
    ECHEMI Editorial Reference
    Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide inhibits human GCGR, GIPR and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively and mouse GCGR, GIPR, and GLP-1R with EC50 values of 2.32, 0.191 and 0.794 nM, respectively. It is an important tool for obesity research.Retatrutide potently activates the GLP-1R signaling pathway to stimulate glucose-dependent insulin secretion through activity at the GIP receptor (GIPR) or the GLP-1R.Retatrutide is a synthetic peptide with glucose-lowering effects. It is an antidiabetic agent against type 2 diabetes (T2D), stimulating insulin and suppressing glucagon secretion in a glucose-dependent manner.Retatrutide was also shown to delay gastric emptying, lower fasting and postprandial glucose concentration, decrease food intake and reduce body weight in patients with type 2 diabetes.

    Certificates

    Basic Info
    Product Name:

    Retatrutide

    Other Name:

    Retatrutide;GIPR/GLP-1R;LY3437943Retatrutide;Retalutide;Retatrutide (sodium salt);Retatrutide RT5;retatrutide 5mg;Retatratide

    CAS No.:

    2381089-83-2

    Molecular Formula:

    C221H342N46O68

    InChIKeys:

    MLOLQJNKXBNWFW-SAGGEDDASA-N

    Molecular Weight:

    4731.33

    EC Number:

    200-001-8

    Color/Form:

    White lyophilized

    Categories:

    Other Chemical Drugs

    Characteristics
    Water Solubility:

    Soluble in water (5mg/ml).

    Storage Conditions:

    -20°C

    Critical Temperature & Pressure:

    -20°C

    Research
    Class:

    Triple agonist — GCGR, GIPR, GLP-1R

    Status:

    Investigational (Phase 3)

    Mechanism:

    Simultaneously activates glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Engineered from the native GIP backbone with amino acid substitutions to confer GCGR and GLP-1R activity.

    EC50 (Human GCGR):

    5.79 nM

    EC50 (Mouse GIPR):

    0.191 nM

    EC50 (Mouse GLP1R):

    0.794 nM

    EC50 (Mouse GCGR):

    2.32 nM

    EC50 (Human GLP1R):

    0.775 nM

    EC50 (Human GIPR):

    0.0643 nM

    Source:

    Jastreboff AM, et al. N Engl J Med. 2023;389(6):514-526.DOI

    Clinical Development:

    NCT04881760; NCT05882045; NCT06354660

    References
    ChEMBL:

    CHEMBL5095485

    DrugBank:

    DB18993

    KEGG DRUG:

    D12430

    PubChem:

    PubChem

    Disclaimer:

    Retatrutide is an investigational compound not yet approved by FDA or EMA. This listing is for industrial and laboratory research use only. Product information on ECHEMI is provided for sourcing and specification reference. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.

  • Seller Information
    Business Type:

    Trader

    Main Products:

    beaty prodt

    Location:

    Yongtai Jinli City Plaza, Baiyun District, Guangzhou City, Guangdong Province

    Payment Terms:

    TT against copy of documents,D/P,L/C,D/A,O/A,TT against B/L draft before shipment,100% TT in advance

    Average lead Time:

    30

    Total Annual Revenue:

    Less than $1 million

    Total Employees:

    5-10

    Year of Establishment:

    2023

  • Inquiry History
    6934 Inquiries
    Country Product Purchase Quantity Date Posted
    United States

    Retatrutide 2381089-83-2

    3 MT Mar 28, 2026
    United Kingdom

    Retatrutide - 2381089-83-2

    1 G Feb 10, 2026
    United States

    Retatrutide CAS 2381089-83-2 10mg vial

    20 MT Mar 7, 2026
    United States

    Factory Retatrutide API 99% Purity CAS 2381089-83-2

    5 KG Nov 10, 2025
    United Kingdom

    Peptide powder Retatrutide 99% pure for Body building cas 2381089-83-2 Weight Loss Peptide with COA

    1 MT Mar 22, 2026
    United States

    2381089-83-2

    100 G Jul 14, 2026
    United States

    2381089-83-2

    100 G Feb 24, 2026
    United States

    2381089-83-2

    100 MT Dec 9, 2023
    United States

    Retatrutide 2381089-83-2

    200 MG May 16, 2026
    United Kingdom

    2381089-83-2 retatrutide

    300 MG Feb 13, 2026
    United States

    Retatrutide 2381089-83-2 wholesale

    500 MT Nov 3, 2023
    United States

    Retatrutide CAS 2381089-83-2 99%

    10 PCS Feb 21, 2026
    Poland

    CAS 2381089-83-2 (Custom Peptide)

    40 MT Apr 10, 2026
    Austria

    Peptide Retatruide CAS 2381089-83-2

    100 MT Apr 4, 2026
    Austria

    Retatrutide CAS 2381089-83-2 10mg vial

    20 PCS Feb 10, 2026
    United States

    GLP-1 / GIP Retatrutide cas 2381089-83-2

    1 MT Oct 16, 2024
    United States

    Retatrutide 99% High Quality CAS 2381089-83-2

    1 G Jan 23, 2026
    United States

    Injection Peptide Tirzepatide/Retatrutide/ Semaglutide Peptides CAS 2381089-83-2

    10  Oct 21, 2023
    Australia

    GMP Grade 99% Retatrutide Lyophilized Powder CAS 2381089-83-2

    10 G Jun 12, 2026
    Palestine

    Factory 99% Purity Retatrutide Peptide CAS 2381089-83-2 Door-To-Door Service

    10 MG Mar 16, 2026
    Post an enquiry for this product
pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.